BeiGene Mourns Death of Beloved Board Member Donald Glazer
BeiGene (NASDAQ: BGNE) announced the passing of Donald Glazer, a Board member and chair of the nominating and corporate governance committee. Glazer, who helped establish the company in 2010, served as a passionate board member and was instrumental in building connections among cancer doctors worldwide. As a founding member, he supported BeiGene's mission to deliver innovative medicines faster and more affordably to patients globally. Despite his personal battle with lung cancer and multiple myeloma, Glazer's impact continues through a family charitable fund.
BeiGene (NASDAQ: BGNE) ha annunciato la scomparsa di Donald Glazer, membro del consiglio e presidente del comitato per le nomine e la governance aziendale. Glazer, che ha contribuito a fondare l'azienda nel 2010, ha servito come un appassionato membro del consiglio ed è stato fondamentale nel creare connessioni tra i medici oncologi in tutto il mondo. In quanto membro fondatore, ha supportato la missione di BeiGene di fornire farmaci innovativi in modo più veloce ed economico ai pazienti a livello globale. Nonostante la sua battaglia personale contro il cancro ai polmoni e il mieloma multiplo, l'impatto di Glazer continua attraverso un fondo benefico familiare.
BeiGene (NASDAQ: BGNE) anunció el fallecimiento de Donald Glazer, un miembro de la junta y presidente del comité de nominaciones y gobernanza corporativa. Glazer, quien ayudó a establecer la empresa en 2010, sirvió como un miembro apasionado del consejo y fue fundamental para construir conexiones entre médicos oncólogos en todo el mundo. Como miembro fundador, apoyó la misión de BeiGene de ofrecer medicamentos innovadores de manera más rápida y asequible a pacientes en todo el mundo. A pesar de su batalla personal contra el cáncer de pulmón y el mieloma múltiple, el impacto de Glazer continúa a través de un fondo benéfico familiar.
BeiGene (NASDAQ: BGNE)는 이사회 멤버이자 지명 및 기업 거버넌스 위원회 의장인 도널드 글레이저의 별세를 발표했습니다. 2010년에 회사를 설립하는 데 도움을 준 글레이저는 열정적인 이사로 활동하며 전 세계의 암 의사들 간의 연결 고리를 구축하는 데 중요한 역할을 했습니다. 창립 멤버로서 그는 BeiGene의 목표인 혁신적인 의약품을 더 빠르고 저렴하게 전 세계 환자에게 제공하는 것을 지지했습니다. 폐암과 다발성 골수종과의 개인적인 싸움에도 불구하고, 글레이저의 영향력은 가족 자선 기금을 통해 계속 이어집니다.
BeiGene (NASDAQ: BGNE) a annoncé le décès de Donald Glazer, membre du conseil d'administration et président du comité des nominations et de la gouvernance d'entreprise. Glazer, qui a aidé à établir l'entreprise en 2010, a été un membre passionné du conseil et a joué un rôle essentiel dans l'établissement de liens entre les oncologues du monde entier. En tant que membre fondateur, il a soutenu la mission de BeiGene de fournir des médicaments innovants plus rapidement et à moindre coût aux patients du monde entier. Malgré son combat personnel contre le cancer du poumon et le myélome multiple, l'impact de Glazer continue à travers un fonds caritatif familial.
BeiGene (NASDAQ: BGNE) gab den Tod von Donald Glazer bekannt, einem Mitglied des Boards und Vorsitzenden des Nominierungs- und Corporate Governance-Ausschusses. Glazer, der 2010 half, das Unternehmen zu gründen, war ein leidenschaftliches Vorstandsmitglied und spielte eine entscheidende Rolle beim Aufbau von Verbindungen zwischen Onkologen weltweit. Als Gründungsmitglied unterstützte er die Mission von BeiGene, innovative Medikamente schneller und günstiger weltweit an Patienten zu liefern. Trotz seines persönlichen Kampfes gegen Lungenkrebs und multiples Myelom bleibt Glazers Einfluss durch einen familiären Wohltätigkeitsfonds bestehen.
- None.
- None.
Co-founder, Chairman and CEO John V. Oyler issued the following statement:
“We are saddened by the passing of our dear friend, Don Glazer. He helped guide the founding of the company in 2010 and was an ardent supporter of our mission to deliver innovative medicines faster and more affordably to patients around the world. His impact from a professional and personal perspective is immeasurable, and he will be deeply missed by all of us who benefited from his extensive experience, sound judgment and wise counsel. We extend our heartfelt condolences to his family during this difficult time.”
Mr. Glazer served as a passionate BeiGene Board member, building connections amongst broad networks of cancer doctors – including his own – around the world. He was a strong proponent of working together across all constituencies in the industry for the betterment of cancer patients. Though he ended his long struggle with lung cancer and multiple myeloma, his legacy continues with a family charitable fund that has made a transformative impact in the lives of many around the world.
About BeiGene
BeiGene is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 10,000 colleagues spans five continents. To learn more about BeiGene, please visit www.beigene.com and follow us on LinkedIn, X (formerly known as Twitter), Facebook and Instagram.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeiGene’s plans, commitments, aspirations and goals under the caption “About BeiGene.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeiGene’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeiGene’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeiGene’s ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene’s subsequent filings with the
To access BeiGene media resources, please visit our News & Media site.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241028061544/en/
Investor
Liza Heapes
+1 857-302-5663
ir@beigene.com
Media
Kyle Blankenship
+1 667-351-5176
media@beigene.com
Source: BeiGene, Ltd.
FAQ
When did Donald Glazer join BeiGene's (BGNE) board of directors?
What was Donald Glazer's role at BeiGene (BGNE)?
What medical conditions did BeiGene (BGNE) board member Donald Glazer face?
